News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Demodexmite_web_0.jpg)
Topical ivermectin study sheds light on dysbiosis in rosacea
- Author:
- Sara Freeman
Research over the past decade has also started to look at the potential role of the skin microbiome in the disease process, but answers have...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Kwatra_Sean_2020_web.jpg)
More phase 3 data support use of nemolizumab for prurigo nodularis
- Author:
- Sara Freeman
"Now I hope you understand why we are so excited," said lead investigator Sonja Ständer, MD.
News
Birch bark–derived treatment reduces daily dressings in patients with epidermolysis bullosa
- Author:
- Sara Freeman
Despite being approved in Europe, Oleogel-S10 has not yet been approved to treat EB in the United States.
News
Roflumilast side effect benefits patients with psoriasis and overweight/obesity
- Author:
- Sara Freeman
An “extraordinary” finding was how some patients’ weight status based on their BMI changed throughout the study.
News
Topical botanical drug coacillium curbs childhood alopecia
- Author:
- Sara Freeman
Coacillium cutaneous solution is also under investigation as a treatment for persistent chemotherapy-induced alopecia, atopic dermatitis, and...
News
Axial spondyloarthritis: Does visibility with x-rays make a difference in management?
- Author:
- Sara Freeman
“Axial spondyloarthritis is one disease, and whether it is radiographic or nonradiographic makes zero difference in the management of the patient...
News
Diagnosing chronic back pain: When to suspect axial spondyloarthritis
- Author:
- Sara Freeman
Worldwide, the average time to diagnosis was found to be up to 6 years, but patient advocacy groups say the delay can be up to 10 years or more....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Kirkham_Bruce_UK_web.jpg)
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis
- Author:
- Sara Freeman
Musculoskeletal symptoms identified in some patients treated with dupilumab for atopic dermatitis could help further understanding of how...
News
Low disease state for childhood lupus approaches validation
- Author:
- Sara Freeman
A new childhood version of the Lupus Low Disease Activity State has been purposefully developed to align with the criteria already used for adults...
News
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
- Author:
- Sara Freeman
In about 5% of patients with seropositive RA, C-reactive protein levels were normal despite disease flares during a 5-year period. The findings...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/163282_Nune_Arvind.jpg)
Long-COVID rate may be higher with rheumatic diseases
- Author:
- Sara Freeman
The results highlight the need for close monitoring and optimized multidisciplinary care for long-term adverse events after COVID-19 in patients...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/163247_Jones_Gareth_T_web.jpg)
NSAID use may mask MRI findings in a quarter of spondyloarthritis cases
- Author:
- Sara Freeman
Among nearly one in four patients whose MRI results were initially positive for sacroiliitis, results were negative 6 weeks after NSAIDs were...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Stovin_Christopher_UK_web_0_0.jpg)
Meta-analysis examines cancer risk concern for JAK inhibitors
- Author:
- Sara Freeman
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/163178_Tian_Zixing_web.jpg)
Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritis
- Author:
- Sara Freeman
There is no difference in the risk of myocardial infarction with interleukin-6 (IL-6) vs. anti–tumor necrosis factor (TNF) therapy for rheumatoid...
News
Cardiovascular risk score multipliers suggested for rheumatic diseases
- Author:
- Sara Freeman
Guidelines could tailor cardiovascular risk scores by using a multiplier of 2.5 for systemic sclerosis, 2.0 for lupus, and 1.5 for any other...